SUMMARY A prospective study of 110 patients with systemic lupus erythematosus (SLE) was undertaken to evaluate the reliability of clinical signs of lupus nephritis, which developed in 39 (35%) patients. Those patients with SLE who showed no clinical signs of lupus nephritis had an excellent survival rate (10 year survival 93%) and retained normal renal function (serum creatinine <130 Rmol/l); clinical lupus nephritis developed mainly in the first three years after diagnosis of SLE and was associated with a decreased survival rate (10 year survival 62%). Increased mortality was found in male patients with lupus nephritis over 25 years of age and in female patients with lupus nephritis under 25 years of age, while renal failure rates did not differ between these groups. Treatment of lupus nephritis with high dose prednisone alone or in combination with immunosuppressants did not result in differences in patient survival or renal function preservation. It was concluded that clinical variables are a reliable guide in the management of patients with SLE, and routine use of renal biopsy in these patients is rejected.
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Nearly all patients with systemic lupus erythematosus (SLE) have histological abnormalities in renal biopsy specimens, 1-3 and sometimes severe proliferative lesions are present without clinical renal abnormalities.4 5 As the occurrence of renal disease is the most important prognostic factor in patients with SLE6 7 the routine use of renal biopsy in all such patients to record glomerular disease and guide treatment has been advocated,4 5 but the issue is highly controversial.8 included in the study and followed up by one of the authors at our lupus outpatient clinics. The clinics started in 1972 and the end point for this study was 
TREATMENT OF LUPUS NEPHRITIS
Treatment of lupus nephritis consisted either of high dose prednisone (1.5 mg/kg) once daily alone (n=16), or in combination with azathioprine (1.5-2-5 mg/kg; n=19) or cyclophosphamide (1-3 mg/kg; n=4). After six weeks prednisone was gradually tapered, while immunosuppressants were continued for at least six months.
HYPERTENSION
Hypertension was considered present when diastolic pressure exceeded 90 mmHg on two different observations and was treated in a stepped-care way with diuretics, i blockers, and vasodilators respectively.
STATISTICS
Statistical evaluation was by Student's *t test for group differences of mean values, the X2 test for absolute numbers, the two tailed Mann-Whitney U test for non-parametric data, and with computerised Kaplan-Meyer analysis of survival curves (STATA). In the calculation of the survival curves for patients with SLE without lupus nephritis death was used as end point, while for curves of patients with SLE and lupus nephritis death and terminal renal insufficiency ('renal death') were taken as end point. Statistical significance was defined as p values <0.05. Unless stated otherwise, values are expressed as mean (SEM).
Results

PATIENT CHARACTERISTICS
Of 110 patients with SLE, 39 (35%) developed clinical lupus nephritis during our study (Table 1) . 4Values are mean (SEM). 
Vp<005. §Values are mean (SEM).
No significant differences were found with respect to sex distribution in either group. Mean age at diagnosis of SLE was significantly lower for patients with lupus nephritis, however, than for those without (33.1 v 40.3 years). Mean follow up for all patients was 89-9 months with no significant differences between groups. The need for renal replacement treatment did not arise in the group without lupus nephritis, whereas eight patients with lupus nephritis needed dialysis (21% of all patients with lupus nephritis). Early treatment with steroids (within two years after SLE was established) was started in 45% of patients, who later developed clinical signs of lupus nephritis (n=20) and in 43-6% of patients who never developed clinical lupus nephritis (p>0-05).
MORTALI.TY
The overall mortality of patients with lupus nephritis was significantly greater than for those without 26% v 6%; p<0-01) ( Table 2 ). This difference was much more pronounced in male than in female patients: male patients with lupus nephritis had a 56% mortality compared with 0% in men without nephritis (p<0-001), whereas female patients with SLE with or without lupus nephritis showed no significant difference in mortality (17% v 6%). Further analysis showed that non-surviving male patients with lupus nephritis were all above 25 years of age at the time of diagnosis, whereas non-surviving female patients with lupus nephritis were mostly younger than 25 years of age. The period between the diagnosis of SLE and the moment of death was significantly 812 Nossent, Bronsveld, Swaak longer in patients without lupus nephritis than in those with the disease (168-5 months v 67-8 months). Figure 2 shows the chance of any patient with SLE in our study developing clinical signs of lupus nephritis. It shows that within the first three years after diagnosis of SLE a patient has a 30% chance of developing lupus nephritis, whereas after this time there is only about a 10% chance. Patients prone to renal insufficiency reached this situation within a short period of time, while others recovered normal renal function; some of these patients (n=8) experienced a second renal exacerbation (mean period after first manifestation 60-2 (SEM 40-1) months) with reversible decrease in The chance of any patient with SLE in our study developing clinical renal disease was 30% for the three year period after the diagnosis of SLE (Fig. 2) 21 Our finding that, regardless of treatment, those patients who will develop terminal renal insufficiency do so in a relatively short period after the diagnosis of lupus nephritis is made, is in accordance with other studies.22 The other patients with lupus nephritis maintained normal renal function and despite a renal exacerbation after four to five years in about 20% of patients normal renal function was maintained throughout the study.
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The fact that patients with SLE without clinical renal disease conserve normal renal function seems obvious but has not been shown elsewhere; in view of the fact that they may well have histological abnormalities of renal tissue'-5 and are at risk for vasculitis and drug induced damage it is reassuring that their survival (Fig. 2) and preservation of renal function (Fig. 1) are not influenced by other manifestations of SLE, and that clinical variables for lupus nephritis are excellent guides for management of patients with SLE.
Hypertension is an important complication and cause of subsequent loss of renal function in lupus nephritis; yet we could not find any relation between the presence of hypertension and severity of renal disease or disease course, which was found by others too.23 24 Probably, the possible deleterious effects of hypertension were recognised and properly treated, thereby eliminating its contribution to renal damage in our patients.
In conclusion, we have shown clinical renal disease to be present in 39 (35%) of our 110 patients with SLE, developing mostly within three years after the diagnosis of SLE, resulting in a decreased survival and increased morbidity compared with patients with SLE without clinical renal disease, who have an excellent prognosis. Survival after treatment of lupus nephritis with high dose prednisone or prednisone combined with immunosuppressants was equally good. Our findings indicate that clinical indices for renal involvement are excellent guides in the management and prognosis of patients with SLE; therefore, the routine use of renal biopsy in patients with SLE is not warranted.
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